Last reviewed · How we verify
GOCOVRI
At a glance
| Generic name | GOCOVRI |
|---|---|
| Sponsor | Oregon Health and Science University |
| Drug class | Influenza A M2 Protein Inhibitor |
| Target | Sigma non-opioid intracellular receptor 1 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Arteriosclerotic Parkinsonism
- Extrapyramidal disease
- Influenza A Prevention
- Influenza due to Influenza A virus
- Parkinson's disease
- Parkinsonism
- Postencephalitic parkinsonism
Common side effects
- Hallucinations
- Dizziness
- Dry mouth
- Peripheral edema
- Constipation
- Fall
- Orthostatic hypotension
- Blurred vision
- Dry mouth (women)
- Peripheral edema (men)
- Dizziness (men)
- Hallucinations (age 65+)
Serious adverse events
- Suicide ideation or attempt
- Somnolence
- Fatigue
- Apathy
- Delusions
- Illusions
- Paranoia
- Cataracts (women)
Drug interactions
- bupropion
Key clinical trials
- Promoting Recovery After STroke With Amantadine (PHASE2)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection
- Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain (PHASE2)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial (PHASE2,PHASE3)
- Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD) (EARLY_PHASE1)
- Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |